ELI LILLY Aktie

 

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market....

Through charitable support of HATCH, United Way Worldwide, United Way of Central Indiana and the Pacers Foundation, the initiative supports efforts to expand access to protein-rich food across communities nationwide, including the creation of infrastructure to deliver an estimated five......

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year...

HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly. Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Consensus estimate, while the telehealth firm swung to a loss of 40 cents a share from a 20-cent profit a year earlier.  HIMS recorded $33.5 million in restructuring charges, including inventory write-downs and transition costs.  "This was an incredibly valuable transition," HIMS CEO Andrew Dudum told analysts on an earnings call. "We are seeing adoption and weight-loss near-record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns." Here's a snapshot o...

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into 'Sell in May' Territory as Pricing Pressures Loom...

Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer's disease.1,2,4,7,8 The same cutoffs (high and low) of the blood test can be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people presenting with symptoms or complaints of cognitive decline.1,2,4,5 The early detection of the amyloid pathology is critical for Alzheimer's diagnosis and treatment, as it enables individuals, families, and caregivers to understand the cause of symptoms, access appropriate care, and actively contribute to the planning of next steps.3,4,5,9,10...

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook....

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly's Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A...

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 11, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before......

The weight loss drug market is on track to reach almost $100 billion....

Here's how a $1,000 bet in Eli Lilly stock turned into a dividend stock powerhouse....

The competition is far behind....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Sanofi, Merck, Bristol Myers Squibb, Eli Lilly, Avalere Health, Deerfield, Havas Media, Omnicom Health Group, Real Chemistry, EVERSANA, Klick Health, Ogilvy Health and others among the firms whose senior leaders co-built Doceree's Daily Command. The product redefines how agencies plan,......

Lilly Endowment Inc - Sonstiges / enge Beziehung - Tag der Transaktion: 2026-05-06...

In a coordinated public declaration at the Doceree Makers Summit, brand and commercial leaders from Sanofi, Merck, Bristol Myers Squibb, Eli Lilly, Avalere Health, Deerfield, and others co-signed a new operating model for pharma marketing — and named the product replacing what they've......

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors....

Mounjaro generated $8.66 billion in sales in the first quarter....

Eli Lilly, Western Digital and Vertiv are drawing attention as AI demand, GLP-1 drugs and data center growth fuel momentum....